Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract...
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
24 sept. 2024 08h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
20 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
19 sept. 2024 16h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
17 sept. 2024 17h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16 sept. 2024 08h30 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
03 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery...
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
23 août 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark ...
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
16 août 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of themOutcome further confirms Bentrio’s...
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
12 août 2024 09h02 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology results in significant reduction in...